Live Deal Pipeline
Deal detail
Browse Samjong KPMG's control sale, investment, and real-estate opportunities in one place.
Healthcare & BiotechPublished deal
Project Organoid - Financing
Developer of non-animal testing, precision-medicine, and regenerative-therapy solutions using hiPSC-based human-mimetic platforms
| Location | Korea |
|---|---|
| Industry | Healthcare & Biotech |
| Revenue | Contact us |
| Asking | KRW 20 billion valuation |
| Deal structure | KRW 5 billion capital raise |
| Financials | Contact us |
Investment highlights
- Positioned to benefit from rapid growth in non-animal testing following the U.S. FDA's removal of mandatory animal-testing requirements
- Models reproduce actual organ functions—including beating, metabolism, and neurotransmission—rather than merely physical appearance
- Developing a cardiac regenerative therapy with demonstrated efficacy in animal studies and potential expansion into additional therapeutics
Deal partner
Hyerim Oh, Manager